For the latest COVID-19 information for Massey, visit


Developmental Therapeutics

The Developmental Therapeutics program consists of more than 45 members, inclusive of treating oncologists and pre-clinical translational scientists. The overarching goal of this program is to leverage basic and translational cancer discoveries emanating from Massey laboratories to develop and implement innovative trials that will ultimately improve the outcomes of cancer patients.

To achieve this goal, program members conduct transdisciplinary and team-science research centered around the following areas:

  1. New Compound Development: Identifying and developing novel drugs or biological agents to target aberrant cancer signaling pathways
  2. Therapeutic Resistance: Investigating mechanisms underlying cancer cell resistance and developing rational combination therapies to overcome this challenge
  3. Clinical Trial Translation: Translating these therapeutic strategies into early and later-stage clinical trials

If you are a researcher with peer-reviewed funding for cancer research, and your science is aligned with the aims of this program, please consider formally applying to become a Massey Cancer Center member.

Learn more about Massey membership.

Program Co-leaders

Steven Grant, M.D.
Professor, Internal Medicine

Anthony Faber, Ph.D.
Associate Professor, Philips Institute for Oral Health Research

Xiang-Yang (Shawn) Wang, Ph.D.
Professor, Human and Molecular Genetics

Research program meetings

View details for upcoming Cancer Biology, Developmental Therapeutics and Cancer Prevention and Control program meetings.

Meeting schedule